Surgical Treatment and Outcome of Ovarian Cancer Patients With Liver Metastases: Experience of a Tertiary Hepatic and Peritoneal Surface Malignancy Center.

Autor:	Acs M; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany; miklos.acs@ukr.de., Herold Z; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary., Neumann L; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany., Slowik P; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany., Evert K; Department of Pathology, University of Regensburg, Regensburg, Germany., Gurok S; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany., Panczel I; Faculty of Medicine, Semmelweis University, Budapest, Hungary., Barna AJ; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.; Department of Obstetrics and Gynecology, Saint Pantaleon Hospital, Dunaujvaros, Hungary., Dank M; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary., Szasz AM; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary., Hornung M; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany., Schlitt HJ; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany., Werner JM; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2024 Feb; Vol. 44 (2), pp. 731-741.
DOI:	10.21873/anticanres.16864
Abstrakt:	Background/aim: The aim of this study was to describe and evaluate the patterns, perioperative outcomes, and survival rates of patients subjected to hepatic resections for ovarian-derived liver metastasis as part of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC). Furthermore, we investigated two subgroups of tumor patterns: hematogenous liver metastasis and infiltrative liver metastatic spread. Patients and Methods: A retrospective study was conducted. Patients from a University Tertiary Hepatic and Peritoneal Surface Malignancy Center with primary or recurrent ovarian cancer, who underwent liver resection as part of cytoreductive surgery between January 1992 and December 2022, were included. Results: Data from 35 patients were analyzed. Both median overall survival (OS) and disease-specific survival (DSS) were 24.97 months. In a multivariate setting, the combined effect of age, peritoneal carcinomatosis index, body mass index, hematogenous liver metastasis vs. infiltrative spread types, and HIPEC (HR=0.2372; 95%CI=0.0719-0.7823; p=0.0181) over OS was tested. Survival analysis revealed no differences between the two metastatic spread types (OS: p=0.9720; DSS: p=0.9610). Younger age (p=0.0301), splenectomy (p=0.0320), lesser omentectomy (p=0.0178), and right upper quadrant peritonectomy (p=0.0373) were more characteristic for those patients with infiltrative liver metastatic spread. Conclusion: Complete cytoreductive surgery, including hepatic resection is a feasible approach with or without additional HIPEC, which may provide survival benefit for patients with advanced and/or recurrent ovarian cancer. If metastatic and infiltrative liver involvement is suspected, liver-specific imaging is recommended. (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu